Anti-tumor necrosis factor a therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: A followup report of tolerability and efficacy

Arthritis and Rheumatism

Volumn 48, Issue 7, 2003, Pages 2019-2024

  Gottenberg, Jacques Eric ^a   Merle Vincent, Florence ^b   Bentaberry, Fabrice ^c   Allanore, Yannick ^d   Berenbaum, Francis ^e   Fautrel, Bruno ^f   Combe, Bernard ^g   Durbach, Antoine ^a   Sibilia, Jean ^h   Dougados, Maxime ^d   Mariette, Xavier ^a  

^a BICÊTRE HOSPITAL   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d Hôpital Cochin ^*  (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g LAPEYRONIE HOSPITAL   (France)

^h HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOLESCENT; ADULT; AMYLOIDOSIS; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GLOMERULUS FILTRATION RATE; HERPES ZOSTER; HISTOLOGY; HUMAN; MALE; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SCHOOL CHILD; TEACHING HOSPITAL;

ADULT; AGED; AMYLOIDOSIS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; APOLIPOPROTEINS; ARTHRITIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROTEINURIA; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SERUM AMYLOID A PROTEIN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037666987     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11163     Document Type: Article

References (12)

1. Shapiro DL, Spiera H. Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine: a case report. Arthritis Rheum 1995;38:1851-4.
2. Komatsuda A, Morita K, Ohtani H, Yamaguchi A, Miura AB. Remission of the nephrotic syndrome in a patient with renal amyloidosis due to rheumatoid arthritis treated with prednisolone and methotrexate. Am J Kidney Dis 1998;32:E7.
3. Savolainen HA. Chlorambucil in severe juvenile chronic arthritis: longterm follow-up with special reference to amyloidosis. J Rheumatol 1999;26:898-903.
4. David J, Vouyiouka O, Ansell BM, Hall A, Woo P. Amyloidosis in juvenile chronic arthritis: a morbidity and mortality study. Clin Exp Rheumatol 1993;11:85-90.
5. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
6. Janssen S, van Rijswijk MH, Meijer S, Ruinen L, van der Hem GK. Systemic amyloidosis: a clinical survey of 144 cases. Neth J Med 1986;29:376-85.
7. Drewe E, McDermott EM, Powell RJ. Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med 2000;343:1044-5.
8. Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002;46:2571-3.
9. Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 2000;7:64-9.
10. Niewold TA, Gruys E, Arakawa T, Shirahama T, Kisilevsky R. Recombinant human tumour necrosis factor-alpha (rhTNF-alpha) and rhTNF-alpha analogue enhance amyloid deposition in the Syrian hamster. Scand J Immunol 1993;37:29-32.
11. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-α through nuclear factor-κB, and by 17β-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000;33: 25781-90.
12. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000;6:643-51.